BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shirato H, Someya Y, Ochiai M, Horiuchi Y, Takahashi M, Takeda N, Wakabayashi K, Ouchi Y, Ota Y, Tano Y, Abe S, Yamazaki S, Wakita T; sIPV Evaluation Group of NIID-Virology II. A national reference for inactivated polio vaccine derived from Sabin strains in Japan. Vaccine 2014;32:5163-9. [PMID: 25090648 DOI: 10.1016/j.vaccine.2014.07.065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Murakami K, Fujii Y, Someya Y. Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats. Vaccine 2020;38:3295-9. [PMID: 32197923 DOI: 10.1016/j.vaccine.2020.03.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Someya Y, Ami Y, Takai-Todaka R, Fujimoto A, Haga K, Murakami K, Fujii Y, Shirato H, Oka T, Shimoike T, Katayama K, Wakita T. Evaluation of the use of various rat strains for immunogenic potency tests of Sabin-derived inactivated polio vaccines. Biologicals 2018;52:12-7. [PMID: 29475730 DOI: 10.1016/j.biologicals.2018.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine 2016;34:1975-85. [PMID: 25448090 DOI: 10.1016/j.vaccine.2014.11.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
4 Kouiavskaia D, Puligedda RD, Dessain SK, Chumakov K. Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines. J Virol Methods 2020;276:113785. [PMID: 31765719 DOI: 10.1016/j.jviromet.2019.113785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Patel M, Zipursky S, Orenstein W, Garon J, Zaffran M. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines 2015;14:749-62. [PMID: 25597843 DOI: 10.1586/14760584.2015.1001750] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
6 Vidor E. Poliovirus Vaccine–Inactivated. Plotkin's Vaccines. Elsevier; 2018. pp. 841-865.e10. [DOI: 10.1016/b978-0-323-35761-6.00047-x] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
7 Crawt L, Atkinson E, Tedcastle A, Pegg E, Dobly A, Wei C, Lei S, Ling P, Li C, Zheng J, Wang Y, Liqun H, Jorajuria S, Cozic G, Ugiyadi D, Kurniati N, Ochiai S, Miyazawa M, Someya Y, Nishihama T, Masafumi M, Westdijk J, Crowe S, Graaf MD, Kouiavskaia D, Chumakov K, Minor P, Cooper G, Rigsby P, Martin J; sIPV Study Group. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays. The Journal of Infectious Diseases 2019. [DOI: 10.1093/infdis/jiz076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]